Development of a minimal saponin vaccine adjuvant based on QS-21

Nature Chemistry

Volumn 6, Issue 7, 2014, Pages 635-643

  Fernández Tejada, Alberto ^a   Chea, Eric K ^a   George, Constantine ^a   Pillarsetty, Nagavarakishore ^a   Gardner, Jeffrey R ^a   Livingston, Philip O ^a,b   Ragupathi, Govind ^a   Lewis, Jason S ^a   Tan, Derek S ^a   Gin, David Y ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Adjuvance Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; QS 21; SAPONIN; VACCINE;

ARTICLE; CHEMISTRY; HUMAN; IMMUNOLOGY; SYNTHESIS;

ADJUVANTS, IMMUNOLOGIC; HUMANS; SAPONINS; VACCINES;

EID: 84903184551     PISSN: 17554330     EISSN: 17554349     Source Type: Journal    
DOI: 10.1038/nchem.1963     Document Type: Article

References (35)

1. Moyle, P. M. & Toth, I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem 8, 360-376 (2013).
2. Leroux-Roels, G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28, C25-C36 (2010).
3. Reed, S. G. et al. New horizons in adjuvants for vaccine development. Trends Immunol. 30, 23-32 (2009).
4. Kensil, C. R., Patel, U., Lennick, M. & Marciani, D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146, 431-437 (1991).
5. Kim, S. K. et al. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine 18, 597-603 (1999).
6. Soltysik, S., Bedore, D. A. & Kensil, C. R. Adjuvant activity of QS-21 isomers. Ann. NY Acad. Sci. 690, 392-395 (1993).
7. 13C NMR spectroscopy. Carbohydr. Res. 280, 1-14 (1996).
8. Ragupathi, G., Gardner, J. R., Livingston, P. O. & Gin, D. Y. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev. Vaccines 10, 463-470 (2011).
9. Agnandji, S. T. et al. First results of Phase 3 trial of RTS,S/AS01 malaria vaccine in African children. New Engl. J. Med. 365, 1863-1875 (2011).
10. Kennedy, J. S. et al. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 26, 4420-4424 (2008).
11. Vandepapeliere, P. et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26, 1375-1386 (2008).
12. Von Eschen, K. et al. The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Hum. Vaccin. 5, 475-482 (2009).
13. Vellas, B. et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 6, 144-151 (2009).
14. Wang, P., Kim, Y. J., Navarro-Villalobos, M., Rohde, B. D. & Gin, D. Y. Synthesis of the potent immunostimulatory adjuvant QS-21A. J. Am. Chem. Soc. 127, 3256-3257 (2005).
15. Deng, K. et al. Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine. Angew. Chem. Int. Ed. 47, 6395-6398 (2008).
16. Adams, M. M. et al. Design and synthesis of potent Quillaja saponin vaccine adjuvants. J. Am. Chem. Soc. 132, 1939-1945 (2010).
17. Chea, E. K. et al. Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes. J. Am. Chem. Soc. 134, 13448-13457 (2012).
18. Soltysik, S. et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 13, 1403-1410 (1995).
19. Seevers, R. H. & Counsell, R. E. Radioiodination techniques for small organic molecules. Chem. Rev. 82, 575-590 (1982).
20. + T cells. J. Immunol. 187, 55-63 (2011).
21. Scott, M. T., Goss-Sampson, M. & Bomford, R. Adjuvant activity of saponin: antigen localization studies. Int. Arch. Allergy Appl. Immunol. 77, 409-412 (1985).
22. Elliott, D. F. & Kon, G. A. R. Sapogenins. VI. Quillaic acid. J. Chem. Soc. 1130-1135 (1939).
23. Nico, D., Santos, F. N., Borja-Cabrera, G. P., Palatnik, M. & Palatnik de Sousa, C. B. Assessment of the monoterpene, glycidic and triterpene-moieties' contributions to the adjuvant function of the CP05 saponin of Calliandra pulcherrima Benth during vaccination against experimental visceral leishmaniasis. Vaccine 25, 649-658 (2007).
24. Castro-Diaz, N. et al. Saponins from the Spanish saffron Crocus sativus are efficient adjuvants for protein-based vaccines. Vaccine 30, 388-397 (2012).
25. Oda, K. et al. Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants. Biol. Chem. 381, 67-74 (2000).
26. Pink, J. R. & Kieny, M. P. Fourth meeting on novel adjuvants currently in/close to human clinical testing. Vaccine 22, 2097-2102 (2004).
27. Kensil, C. R. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst. 13, 1-55 (1996).
28. Marciani, D. J. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today 8, 934-943 (2003).
29. Nimmerjahn, F. & Ravetch, J. V. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310, 1510-1512 (2005).
30. Kensil, C. R. & Kammer, R. QS-21: a water-soluble triterpene glycoside adjuvant. Exp. Opin. Invest. Drugs 7, 1475-1482 (1998).
31. Bomford, R. Studies on the cellular site of action of the adjuvant activity of saponin for sheep erythrocytes. Int. Arch. Allergy Appl. Immunol. 67, 127-131 (1982).
32. Calabro, S. et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29, 1812-1823 (2011).
33. Dupuis, M., McDonald, D. M. & Ott, G. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine 18, 434-439 (1999).
34. Dupuis, M. et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell. Immunol. 186, 18-27 (1998).
35. Kim, S-K., Ragupathi, G., Cappello, S., Kagan, E. & Livingston, P. O. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine 19, 530-537 (2000).